Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Follow-Up Questions
Prostatype Genomics AB 的 CEO 是誰？
Fredrik Persson 是 Prostatype Genomics AB 的 Chief Executive Officer，自 2017 加入公司。
PGABF 股票的價格表現如何？
PGABF 的當前價格為 $0，在上個交易日 decreased 了 0%。
Prostatype Genomics AB 的主要業務主題或行業是什麼？
Prostatype Genomics AB 屬於 Biotechnology 行業，該板塊是 Health Care
